G1 Therapeutics steered a first-of-its-kind lung cancer drug to FDA approval, but long maintained that development and commercialization globally would require partnerships. There’s a new path forward ...

G1 Therapeutics, Inc. faces a setback as a trial for triple-negative breast cancer fails to improve survival, leading to a significant market selloff. The company's main drug, trilaciclib, shows ...

June 24 (Reuters) - G1 Therapeutics (GTHX.O), opens new tab said on Monday its drug for a rare, aggressive form of breast cancer did not meet the main goal of overall survival in a late-stage trial.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min G1 Therapeutics is looking to ...

Shares of G1 Therapeutics Inc (NASDAQ:GTHX) are trading lower after the company released topline results from the final OS analysis of its Phase 3 PRESERVE 2 trial evaluating the efficacy and safety ...

Top-line phase III data from G1 Therapeutics Inc.’s pivotal Preserve 2 study of Cosela (trilaciclib) in treating metastatic triple-negative breast cancer missed its primary endpoint of overall ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min G1 Therapeutics scores big again ...

G1 Therapeutics (NASDAQ:GTHX) fell ~7% premarket Tuesday after announcing that its Phase 3 PRESERVE 2 trial for its experimental breast cancer therapy trilaciclib did not reach its main goal related ...